Clinical Trials Logo

Filter by:
NCT ID: NCT06168071 Enrolling by invitation - Clinical trials for Hypoxia-Ischemia, Brain

Transauricular Vagus Nerve Stimulation in Children

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about brain waves during transauricular vagus nerve stimulation (taVNS) in healthy children. The main questions it aims to answer are: - What is the safety, tolerability, and physiological response of taVNS in children? - Does the electroencephalogram (EEG) change during taVNS? Participants will - undergo a brief titration session where taVNS will be titrated to below perceptual threshold - receive one session of 30 minutes of taVNS - undergo clinical EEG monitoring during taVNS - Continuous cardiorespiratory monitoring via pulse oximetry and blood pressure every 5 minutes - Answer tolerability questions before, during and after 30 minute taVNS session

NCT ID: NCT06167642 Enrolling by invitation - Multiple Sclerosis Clinical Trials

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Start date: May 22, 2023
Phase:
Study type: Observational

This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.

NCT ID: NCT06164951 Enrolling by invitation - Achondroplasia Clinical Trials

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

PROPEL3
Start date: November 10, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of participation in the QED-sponsored study PROPEL (QBGJ398-001).

NCT ID: NCT06164756 Enrolling by invitation - Depression Clinical Trials

Long Term Follow Up KET-PD

Start date: October 18, 2023
Phase:
Study type: Observational

The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.

NCT ID: NCT06164392 Enrolling by invitation - Neuroma Clinical Trials

Evaluation of Neuroma Perfusion With Indocyanine Green Fluorescence Angiography

Start date: February 29, 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to characterize the perfusion of neuromas using indocyanine green fluorescence angiography

NCT ID: NCT06163508 Enrolling by invitation - Transverse Myelitis Clinical Trials

A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells

Start date: December 12, 2023
Phase:
Study type: Observational

This study is an observational study designed to obtain information on the long-term safety, tolerability, and continued activity of Q-Cells®. The study will follow the participants who previously received Q-Cells® for 10 years. The goal of this observational study is to learn about the long term effects of Q-Cells® in people with transverse myelitis. The main objectives the study is to evaluate the safety of patients who have received Q-Cells®. The secondary goal of the study is to get data about the long-term activity of Q-Cells® over a period of 10 years. Patients will complete exams, lab tests, imaging, and questionnaires to monitor their safety.

NCT ID: NCT06162585 Enrolling by invitation - Clinical trials for Retinitis Pigmentosa

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

REMAIN
Start date: December 8, 2023
Phase:
Study type: Observational

This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Eligible subjects will be consented to return for scheduled study visits for this study following their completion in study NTXMCO-002 (RESTORE). They will not receive a second treatment with MCO-010 (or a repeated sham injection) in this study

NCT ID: NCT06161597 Enrolling by invitation - Clinical trials for Families of Middle School Students at Title 1 Schools

Family Check-Up Online

FCO
Start date: October 25, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the benefits of the Family Check-Up Online Program for parents of middle school students in Arizona. Participants will complete an online pre-survey, gain access to the online parenting program Family Check-Up, and have the option to meet with a coach to discuss the program. The participants will also complete a post-survey 3 months after enrollment.

NCT ID: NCT06160349 Enrolling by invitation - Infections Clinical Trials

EnCoRe MoMS:Engaging Communities to Reduce Morbidity From Maternal Sepsis

Start date: July 20, 2023
Phase:
Study type: Observational

Sepsis is the second leading cause of maternal death in the U.S. For racial and ethnic minoritized birthing people, especially those who are Black, living in poverty, and from underserved communities, labor and postpartum are particularly vulnerable risk periods. The goal of this multi-center, multidisciplinary observational study is to establish a novel maternal care continuity model to reduce sepsis- related death and disability and increase maternal health equity.

NCT ID: NCT06157671 Enrolling by invitation - Clinical trials for Pancreatic Adenocarcinoma

The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma

Start date: January 31, 2024
Phase:
Study type: Observational

Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions. The test involves ultrasound and an analysis of pancreatic juice. A neural network-based computer-assisted system may be utilized to enhance the analysis. Patients enrolled are being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes).